Summit Therapeutics Inc. (SMMT) posted a GAAP net loss in the third quarter of $231.8 million or$0.31 per share, compared to a loss of $56.3 million or$0.08 per share, a year ago. Non-GAAP net loss in the third quarter was $101.0 million or$0.13 per compared to a loss of $36.9 million or$0.05 per share, prior year.Summit also announced that, based on the results of the HARMONi clinical trial, it plans to submit a Biologics License Application in order to seek approval for ivonescimab plus chemotherapy. ...